Command Palette

Search for a command to run...

Preprint WatchStrongOctober 1st, 2026

Disrupting aberrant EGFR catalytic trimers reverses T790M gefitinib resistance

Roberts, S. K.; Galdadas, I.; Piasentin, N.; Needham, S. R.; Zanetti-Domingues, L. C.; Davis, B. M.; Man, R. C. H.; Clarke, D. T.; Clayton, A. H. A.; Rolfe, D. J.; Fruhwirth, G. O.; Gervasio, F. L.; Martin-Fernandez, M. L.

TKI-resistant EGFR variants assemble into ligand-free higher-order oligomers organised around pathological catalytic trimers, and genetically disrupting those trimers into dimers reverses gefitinib resistance in vivo.

Strong contradiction

3 prior failures

Three or more documented clinical failures match this mechanism, or a Phase 3 efficacy failure is on record.

This preprint reports a structural mechanism for acquired EGFR TKI resistance, in which resistant variants form catalytic trimers and converting them to dimers by a single point mutation reverses gefitinib resistance in vivo. The Claidex graph records three EGFR failures spanning distinct modalities: the TAK-186 CD3 bispecific efficacy failure (tak-186-mvc-101-egfr-cd3-cobra-solid-tumors-phase1-2-efficacy-failure), the FPI-2107 radioconjugate dosimetry and uptake failure (fpi-2107-egfr-cmet-nsclc-dosimetry-uptake-failure), and the BG-60366 degrader shutdown (bg-60366-egfr-cdac-nsclc-strategic-shutdown). EGFR is validated as a target, so the recurring failure mode in that record is modality rather than biology. The claim here is genetic proof of concept, a point mutation rather than a drug, and no molecule is shown to disrupt the trimer pharmacologically. That gap between a genetic manipulation and a tractable binding site is precisely where the three recorded EGFR programmes lost their margin, which is why this is flagged STRONG rather than treated as a ready therapeutic hypothesis.

Abstract excerpt

Epidermal growth factor receptor (EGFR) mutations drive up to 50% of non-small-cell lung cancers (NSCLC). Although tyrosine kinase inhibitors (TKIs) like gefitinib initially offer substantial clinical benefit, the emergence of acquired, on-target resistance inevitably limits long-term remission. Beyond structural changes that alter ATP-pocket affinity, EGFR oligomerization drives this resistance, though the underlying mechanisms remain unclear. Here we show that progressive, TKI-resistant secondary and tertiary EGFR-mutant variants assemble on the cell surface into higher-order, ligand-free oligomers organized around pathological catalytic trimers. In contrast, gefitinib-sensitive variants assemble into oligomers where the catalytic units remain as canonical dimers, like those found in wild-type oligomers. Genetically disrupting these pathological trimers into dimers via a single-point mutation rewires downstream signaling, decelerates tumor progression, and reverses gefitinib resistance in vivo. Conversely, genetic engineering of dimers into trimers reinstates aggressive tumor growth. These findings expose a structural vulnerability unique to acquired mutations, demonstrating that selectively targeting these pathological intra-oligomer trimers can overcome resistance, and provide a blueprint for protein-protein interface modulation strategies that spare wild-type signaling.

Matching Claidex post-mortems

3 of 3 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.